Showing results (61-70 of 345) with videos related to
Sort By:
Pageof 35
Journal of Neurology|January 3, 2024
Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS RegistryLorena Lorefice, Ottavia Elena Ferraro, Giuseppe Fenu, et al.Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|February 11, 2026
Refining predictors of long-term NEDA-3 status in relapsing-remitting multiple sclerosis: insights from real-world dataTommaso Guerra, Antonella Bianco, Chiara Esposto, et al.Journal of Neurology|July 29, 2026
Prognostic factors in paediatric-onset multiple sclerosis: a narrative reviewMariaclara Achille, Massimiliano Copetti, Tommaso Guerra, et al.BMC Psychology|July 29, 2025
The protective role of cognitive reserve in moderating depressive symptomatology in patients with multiple sclerosisMadia M Biasi, Paolo Taurisano, Alessia Manni, et al.Investigative Ophthalmology & Visual Science|March 26, 2005
Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivityDario Sisto, Maria Trojano, Michele Vetrugno, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|January 22, 2014
Pregnancy, sex and hormonal factors in multiple sclerosisDavid H Miller, Franz Fazekas, Xavier Montalban, et al.Journal of Neurology|April 1, 2024
Big Multiple Sclerosis Data network: an international registry research networkAnna Glaser, Helmut Butzkueven, Anneke van der Walt, et al.European Neurology|October 4, 2014
Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlightsMaria Trojano, Elisabeth G Celius, Cecile Donzé, et al.Multiple Sclerosis and Related Disorders|June 12, 2023
Influence of physicians' risk perception on switching treatments between high- efficacy and non-high-efficacy disease‑modifying therapies in multiple sclerosisGustavo Seifer, Tarunya Arun, Carlos Capela, et al.Journal of Clinical Pharmacology|April 24, 2015
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing studyDamiano Paolicelli, Alessia Manni, Vita Direnzo, et al.Pageof 35